CSIMarket
 
Sanofi  (SNY)
Other Ticker:  
 
 
Price: $51.2600 $-1.59 -3.009%
Day's High: $51.74 Week Perf: -3.06 %
Day's Low: $ 50.85 30 Day Perf: -6.55 %
Volume (M): 3,013 52 Wk High: $ 58.97
Volume (M$): $ 154,467 52 Wk Avg: $50.36
Open: $51.47 52 Wk Low: $45.13



 Market Capitalization (Millions $) 64,403
 Shares Outstanding (Millions) 1,256
 Employees 100,000
 Revenues (TTM) (Millions $) 52,017
 Net Income (TTM) (Millions $) 6,088
 Cash Flow (TTM) (Millions $) 14,264
 Capital Exp. (TTM) (Millions $) 0

Sanofi
Sanofi is a multinational pharmaceutical company that is headquartered in Paris, France. The company was founded in 1973 and has since become one of the largest pharmaceutical companies in the world, with a presence in over 170 countries. The company specializes in research, development, and manufacturing of pharmaceutical drugs, vaccines, and medical devices. It is committed to addressing societal health challenges, improving patient access to medicines, and contributing to global health initiatives.

Sanofi has a diversified portfolio of products in the areas of cardiovascular disease, diabetes, oncology, immunology, and rare diseases. Its products range from prescription medicines to consumer healthcare products, and it invests heavily in research and development to discover new treatments and improve existing ones. In 2020, the company reported a total revenue of e36.1 billion ($42.7 billion).

Sanofi operates through three business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment develops and manufactures prescription drugs for a wide range of health conditions, including cardiovascular disease, oncology, diabetes, immunology, and rare diseases. The Consumer Healthcare segment produces over-the-counter medications, vitamins, and other health and wellness products. The Vaccines segment focuses on developing and manufacturing innovative vaccines to prevent and treat infectious diseases, including influenza, meningitis, and human papillomavirus (HPV).

As a socially responsible company, Sanofi is focused on improving patient access to medicine, reducing healthcare disparities, and fighting against diseases that disproportionately affect vulnerable populations. The company has a strong commitment to sustainability, biodiversity, and reducing its environmental impact. In 2020, Sanofi was recognized as one of the world's most ethical companies by the Ethisphere Institute.

Sanofi has a global workforce of over 100,000 employees and maintains a diverse and inclusive workplace culture. The company actively supports employee development and well-being, with initiatives that promote work-life balance, diversity, and inclusion. Sanofi is also committed to investing in the communities where it operates, with programs that support education, healthcare, and access to medicine.

In summary, Sanofi is a leading pharmaceutical company that is committed to discovering and manufacturing life-saving treatments and therapies for a wide range of health conditions. With a strong focus on sustainability, social responsibility, and employee well-being, Sanofi is a leader in the pharmaceutical industry and a trusted partner in global healthcare.


   Company Address: 46, avenue de la Grande Armée Paris 75017
   Company Phone Number: 1 53 77 40 00   Stock Exchange / Ticker: NASDAQ SNY


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AZN   -10.26%    
BMY        1.04% 
MRK   -0.61%    
NVS   -1.47%    
PFE   -2.47%    
GILD        8.93% 
• View Complete Report
   



Sanofi

Sanofi's Shares See Decline, But Collaboration with Innate Pharma Sparks Hope for Future Growth

Sanofi, a major pharmaceutical preparations company, has been experiencing a decline in its shares over the past 30 days. With a decrease of -10.99% in its share price, the year-to-date performance has been affected, reaching -7.64%. Additionally, the company's shares are trading only 8.3% above its 52-week low. However, despite these challenges, Sanofi recently announced a significant milestone in its collaboration with Innate Pharma, a leading biotechnology company.
Innate Pharma disclosed that Sanofi has exercised its option to license a natural killer (NK) cell engager program in solid tumors from Innate's innovative ANKET platform. This collaboration aims to harness the power of the immune system to fight cancer, which is a highly sought-after area for innovative cancer treatments. This development is a crucial step forward in the quest for effective cancer therapies.

Product Service News

Innate Pharma and Sanofi Enter a New Era of Collaboration in Oncology Research

Published Tue, Dec 19 2023 6:00 AM UTC


Innate Pharma, a leading biotechnology company focused on harnessing the power of the immune system to fight cancer, announced today a significant milestone in its collaboration with Sanofi. The French-based company revealed that Sanofi has exercised its option to license a natural killer (NK) cell engager program in solid tumors from Innate's innovative ANKET (Antibody...







Sanofi's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com